URGN logo

URGN
UroGen Pharma Ltd

2,284
Mkt Cap
$1.05B
Volume
1.07M
52W High
$30.00
52W Low
$3.42
PE Ratio
-6.72
URGN Fundamentals
Price
$21.57
Prev Close
$20.53
Open
$21.40
50D MA
$19.66
Beta
1.05
Avg. Volume
900,894.33
EPS (Annual)
-$3.19
P/B
-9.89
Rev/Employee
$377,278.35
$1,135.16
Loading...
Loading...
News
all
press releases
Urogen Pharma (NASDAQ:URGN) Shares Gap Up - Time to Buy?
Urogen Pharma (NASDAQ:URGN) Shares Gap Up - Still a Buy...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Jefferies Financial Group Initiates Coverage on Urogen Pharma (NASDAQ:URGN)
Jefferies Financial Group began coverage on Urogen Pharma in a research note on Friday. They issued a "buy" rating and a $40.00 price objective on the stock...
MarketBeat·2d ago
News Placeholder
Urogen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reissued a "buy" rating and set a $33.00 price target on shares of Urogen Pharma in a report on Tuesday...
MarketBeat·12d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN
Hennion & Walsh Asset Management Inc. increased its holdings in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 148.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,924 shares of the com...
MarketBeat·12d ago
News Placeholder
Urogen Pharma $URGN Shares Acquired by JPMorgan Chase & Co.
JPMorgan Chase & Co. raised its stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 36.9% during the 3rd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·14d ago
News Placeholder
SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN
SG Americas Securities LLC increased its position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 19.0% during the 4th quarter, according to its most recent 13F filing with the Securities...
MarketBeat·17d ago
News Placeholder
Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned...
MarketBeat·18d ago
News Placeholder
JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN
JPMorgan Chase & Co. raised its stake in Urogen Pharma (NASDAQ:URGN - Free Report) by 36.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission...
MarketBeat·1mo ago
News Placeholder
Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat
Urogen Pharma (NASDAQ:URGN) Shares Gap Up on Better-Than-Expected Earnings...
MarketBeat·1mo ago
News Placeholder
Urogen Pharma (NASDAQ:URGN) Shares Down 13.5% - Should You Sell?
Urogen Pharma (NASDAQ:URGN) Shares Down 13.5% - Time to Sell...
MarketBeat·1mo ago
<
1
2
...
>

Latest URGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.